Table 2.

Baseline patient characteristics

Characteristicn = 67
Age at diagnosis (y); median (range) 15 (4-20) 
Age at relapse/refractory disease (y); median (range) 17 (8-21) 
Sex 
Female 34 (51%) 
Male 33 (49%) 
Relapse or refractory  
Relapsed disease 43 (64%) 
Refractory disease 24 (36%) 
Timing of initial relapse 
Relapse <12 months 27 (64%) 
Relapse ≥12 months 15 (36%) 
Unknown 
Stage at relapse 
2 (3%) 
II 31 (47%) 
III 7 (11%) 
IV 26 (39%) 
Unknown 
B symptoms 13 (19%) 
Bulk disease 20 (30%) 
Extranodal disease 23 (35%) 
Salvage regimens before ASCT 
50 (75%) 
12 (18%) 
5 (7%) 
Treatment with brentuximab before ASCT 
At any time 46 (69%) 
Immediately before ASCT 41 (61%) 
PET response before ASCT 
Negative 45 (69%) 
Positive 20 (31%) 
Unknown 
BMT conditioning 
BEAM 40 (60%) 
CBV 10 (15%) 
Other  17 (25%) 
RT given in salvage 30 (45%) 
Characteristicn = 67
Age at diagnosis (y); median (range) 15 (4-20) 
Age at relapse/refractory disease (y); median (range) 17 (8-21) 
Sex 
Female 34 (51%) 
Male 33 (49%) 
Relapse or refractory  
Relapsed disease 43 (64%) 
Refractory disease 24 (36%) 
Timing of initial relapse 
Relapse <12 months 27 (64%) 
Relapse ≥12 months 15 (36%) 
Unknown 
Stage at relapse 
2 (3%) 
II 31 (47%) 
III 7 (11%) 
IV 26 (39%) 
Unknown 
B symptoms 13 (19%) 
Bulk disease 20 (30%) 
Extranodal disease 23 (35%) 
Salvage regimens before ASCT 
50 (75%) 
12 (18%) 
5 (7%) 
Treatment with brentuximab before ASCT 
At any time 46 (69%) 
Immediately before ASCT 41 (61%) 
PET response before ASCT 
Negative 45 (69%) 
Positive 20 (31%) 
Unknown 
BMT conditioning 
BEAM 40 (60%) 
CBV 10 (15%) 
Other  17 (25%) 
RT given in salvage 30 (45%) 

BEAM, carmustine, etoposide, cytarabine, melphalan; CBV, carmustine, cyclophosphamide, etoposide.

Other BMT conditioning regimens included gemcitabine, busulfan, melphalan, and vorinostat (8 patients); busulfan, gemcitabine, and melphalan (4 patients); etoposide and melphalan (3 patients); and cyclophosphamide and etoposide (2 patients).

Close Modal

or Create an Account

Close Modal
Close Modal